American Journal of Kidney Diseases
Volume 53, Issue 5 , Pages 890-894 , May 2009

Argyria and Decreased Kidney Function: Are Silver Compounds Toxic to the Kidney?

  • Michael Mayr, MD

      Affiliations

    • Clinic for Transplantation Immunology and Nephrology, University Hospital, Basel, Switzerland
    • Corresponding Author InformationAddress correspondence to Michael Mayr, MD, Clinic for Transplantation Immunology and Nephrology, University Hospital Basel, CH-4031 Basel, Switzerland
    • ,
  • Min Jeong Kim, MD

      Affiliations

    • Clinic for Internal Medicine, University Hospital, Basel, Switzerland
    • ,
  • Daniel Wanner, MD

      Affiliations

    • Clinic for Rheumatology, University Hospital, Basel, Switzerland
    • ,
  • Hopfer Helmut, MD

      Affiliations

    • Institute for Pathology, University Hospital, Basel, Switzerland
    • ,
  • Josef Schroeder, MD

      Affiliations

    • Center for Electron Microscopy, University Hospital Regensburg, Regensburg, Germany
    • ,
  • Michael J. Mihatsch, MD

      Affiliations

    • Institute for Pathology, University Hospital, Basel, Switzerland

Received 2 June 2008 ,Accepted 14 August 2008.

References 

  1. Drake PL, Hazelwood KJ. Exposure-related health effects of silver and silver compounds: A review. Ann Occup Hyg. 2005;49:575–585
  2. Agency for Toxic Substances and Disease Registry (ATSDR). Toxicological profile for silver (TP-90-24). Atlanta, GA: ATSDR; 1990;
  3. Venugopal B, Luckey TP. Toxicology of non-radioactive heavy metals and their salts. Environ Qual Saf Suppl. 1975;1:S4–S14
  4. Pifer JW, Friedlander BR, Kintz RT, et al. Absence of toxic effects in silver reclamation workers. Scand J Work Environ Health. 1989;15:210–221
  5. Rosenman KD, Seixas N, Jacobs I. Potential nephrotoxic effects of exposure to silver. Br J Ind Med. 1987;44:267–272
  6. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31–41
  7. Frequenz- und Blutstrom-Zapper mit Silberkolloid–Body World Fitness-Shop. [Body World website] http://www.bodyworld.ch/zapper-und-silberkolloid.htmlAccessed August 2, 2008
  8. Kapp N, Studer D, Gehr P, et al. Electron energy-loss spectroscopy as a tool for elemental analysis in biological specimens. Methods Mol Biol. 2007;369:431–447
  9. Schroeder JA, Weingart C, Coras B, et al. Ultrastructural evidence of dermal gadolinium deposits in a patient with nephrogenic systemic fibrosis and end-stage renal disease. Clin J Am Soc Nephrol. 2008;3:968–975
  10. Keast VJ, Bosman M. New developments in electron energy loss spectroscopy. Microsc Res Tech. 2007;70:211–219
  11. Gettler AO, Rhoads CP, Weiss S. A contribution to the pathology of generalized argyria with a discussion of the fate of silver in the human body. Am J Pathol. 1927;3:631–651
  12. Jonas L, Bloch C, Zimmermann R, et al. Detection of silver sulfide deposits in the skin of patients with argyria after long-term use of silver-containing drugs. Ultrastruct Pathol. 2007;31:379–384
  13. Tomi NS, Kranke B, Aberer W. A silver man. Lancet. 2004;363:532
  14. Jahn . Ueber Argyrie. Beitr Path Anat. 1894;16:218–239
  15. Walker F. Basement-membrane turnover in man. J Pathol. 1972;107:123–125
  16. Zollinger HU. Niere und ableitende Harnwege. In: Heidelberg, Germany: Springer Verlag; 1966;p. 282
  17. Walker F. Experimental argyria: A model for basement membrane studies. Br J Exp Pathol. 1971;52:589–593
  18. Rosenman KD, Moss A, Kon S. Argyria: Clinical implications of exposure to silver nitrate and silver oxide. J Occup Med. 1979;21:430–435
  19. Chaby G, Viseux V, Poulain JF, et al. [Topical silver sulfadiazine-induced acute renal failure]. Ann Dermatol Venereol. 2005;132:891–893
  20. Maitre S, Jaber K, Perrot JL, et al. [Increased serum and urinary levels of silver during treatment with topical silver sulfadiazine]. Ann Dermatol Venereol. 2002;129:217–219
  21. Owens CJ, Yarbrough DR, Brackett NC. Nephrotic syndrome following topically applied sulfadiazine silver therapy. Arch Intern Med. 1974;134:332–335
  22. Watanabe Y, Eguchi A, Kamio M, et al. [Case of membranous nephropathy associated with argyria]. Nippon Jinzo Gakkai Shi. 2005;47:547–551
  23. Zech P, Colon S, Labeeuw R, et al. [Nephrotic syndrome with silver deposits in the glomerular basement membranes during argyria]. Nouv Presse Med. 1973;2:161–164
  24. Berry JP, Dennebouy R, Chaintreau M, et al. Scanning ion microscopy mapping of basement membrane elements and arterioles in the kidney after selenium-silver interaction. Cell Mol Biol (Noisy-le-grand). 1995;41:265–270
  25. Day WA, Hunt JS, McGiven AR. Silver deposition in mouse glomeruli. Pathology. 1976;8:201–204
  26. Lansdown AB. Silver in health care: Antimicrobial effects and safety in use. Curr Probl Dermatol. 2006;33:17–34
  27. Department of Health and Human ServicesFood and Drug Administration. Over-the-counter drug products containing colloidal silver ingredients or silver salts (21 CFR Part 310, Rules and Regulations. FR Doc. 99-21253, 44653-44658). 1999;
  28. Jacobs R. Argyria: My life story. Clin Dermatol. 2006;24:66–69

 Originally published online as doi:10.1053/j.ajkd.2008.08.028 on November 3, 2008.

PII: S0272-6386(08)01354-1

doi: 10.1053/j.ajkd.2008.08.028

American Journal of Kidney Diseases
Volume 53, Issue 5 , Pages 890-894 , May 2009

Article Tools

* Image Usage & Resolution